UP!
 |
|
| Industry | Biotechnology |
|---|---|
| Founded | 2009 |
| Headquarters | Berkeley Heights, NJ, U.S. |
|
Key people
|
Brian Leuthner (President & CEO) R Loch Macdonald (Chief Scientific Officer) |
| Website | http://www.edgetherapeutics.com |
Brian Leuthner (President & CEO)
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, Edge's lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, Edge's second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.
EG-1962 and EG-1964 both utilize Edge’s proprietary, programmable, biodegradable polymer-based development platform, known as Precisa™. The Precisa platform allows Edge to create therapeutics capable of delivering medicines directly to the site of injury, providing a novel delivery mechanism that enables targeted and sustained drug exposure while potentially avoiding the systemic, dose-limiting side effects often associated with current standards of care.
| 2016-05-09 | Lower Price Target | Credit Suisse | Outperform | $19.00 to $18.00 |
| 2016-05-09 | Lower Price Target | Credit Suisse Group AG | Outperform | $19.00 to $18.00 |
| 2016-03-11 | Reiterated Rating | Leerink Swann | Outperform | $27.00 to $24.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $34.00 to $18.00 |
| 2015-10-26 | Initiated Coverage | Guggenheim | Buy | $30.00 |
| 2015-10-26 | Initiated Coverage | JMP Securities | Outperform | $34.00 |
| 2015-10-26 | Initiated Coverage | Leerink Swann | Outperform | $27.00 |
| 2015-10-26 | Initiated Coverage | Credit Suisse | Outperform | $29.00 |
| 2016-05-09 | Lower Price Target | Credit Suisse | Outperform | $19.00 to $18.00 |
| 2016-05-09 | Lower Price Target | Credit Suisse Group AG | Outperform | $19.00 to $18.00 |
| 2016-03-11 | Reiterated Rating | Leerink Swann | Outperform | $27.00 to $24.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $34.00 to $18.00 |
| 2015-10-26 | Initiated Coverage | Guggenheim | Buy | $30.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In EDGE 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM